EcoDrugPlus

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSCVAG00000013489
Gene Symbol: LOC107089824
3 Cross references
360 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSCVAG00000006714
Gene Symbol: SLC29A1
1 Cross references
207 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSCVAG00000019617
Gene Symbol: SLC29A1
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSCVAG00000006118
Gene Symbol: SLC5A2
3 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSCVAG00000018519
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSCVAG00000020218
Gene Symbol: SLC6A3
3 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSCVAG00000014681
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSCVAG00000009134
Gene Symbol: SLC6A9
3 Cross references
207 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSCVAG00000011058
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSCVAG00000014506
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 5

Ensembl ID : ENSCVAG00000002003
Gene Symbol: SSTR5
3 Cross references
187 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSCVAG00000008291
Gene Symbol: SPHK2
2 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).